TITLE

O3–049SYNERGISTIC INTERACTION BETWEEM OLAPARIB, A PARP INHIBITOR, AND CYTOTOXIC AGENT IN TRIPLE NEGATIVE BREAST CANCER

AUTHOR(S)
Hashimoto, J.; Kitamura, Y.; Takashima, Y.; Kodera, Y.; Shimma, S.; Hamada, A.; Fujiwara, Y.; Koizumi, F.; Tamura, K.
PUB. DATE
November 2013
SOURCE
Annals of Oncology;Nov2013 Supplement 9, Vol. 24, pix59
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
92604623

 

Related Articles

  • Structure-Based Development of Small Molecule PFKFB3 Inhibitors: A Framework for Potential Cancer Therapeutic Agents Targeting the Warburg Effect. Seo, Minsuh; Kim, Jeong-Do; Neau, David; Sehgal, Inder; Lee, Yong-Hwan // PLoS ONE;2011, Vol. 6 Issue 9, p1 

    Cancer cells adopt glycolysis as the major source of metabolic energy production for fast cell growth. The HIF-1-induced PFKFB3 plays a key role in this adaptation by elevating the concentration of Fru-2,6-BP, the most potent glycolysis stimulator. As this metabolic conversion has been suggested...

  • Addition of carboplatin, bevacizumab to neoadjuvant regimen increased response in triple-negative breast cancer. Altersitz, Katrina; Todak, Alexandra // Hem/Onc Today;1/25/2014, Vol. 15 Issue 2, p24 

    The article discusses a randomized, phase 2 trial led by William M. Sikov, which indicates that adding carboplatin alone, bevacizumab alone, or a combination of both to neoadjuvant chemotherapy increased the rate of pathologic complete response in female triple-negative breast cancer patients.

  • Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.  // Breast Cancer Research;2011, Vol. 13 Issue 4, p3072 

    The article focuses on a study which examined the association of tumor-infiltrating lymphocytes (TIL) with short-term and long-term clinical response to anthracycline-based therapy in two independent estrogen receptor-alpha (ER)-negative breast cancer cohorts. Publically available gene...

  • Clinical Effect of Irinotecan in Advanced and Metastatic Breast Cancer Patients Previously Treated with Doxorubicin- and Docetaxel-containing Regimens. Shigeoka, Yasushi; Itoh, Kuniaki; Igarashi, Tadahiko; Ishizawa, Kenichi; Saeki, Toshiaki; Fujii, Hirofumi; Minami, Hironobu; Imoto, Shigeru; Sasaki, Yasutsuna // Japanese Journal of Clinical Oncology;Aug2001, Vol. 31 Issue 8, p370 

    Background: Previous phase II trials in Japan suggested that irinotecan was a promising agent for advanced or metastatic breast cancer pretreated with anthracycline. However, irinotecan has not yet been evaluated in the salvage setting for breast cancer pretreated with both anthracycline and...

  • HOMOLOGY MODELLING, VALIDATION AND DOCKING OF DFHR WITH BREAST CANCER INHIBITORS. Vardhini, Shailima R. D. // Journal of Pharmaceutical & Scientific Innovation;Mar/Apr2014, Vol. 3 Issue 2, p158 

    Proteins are the biomolecules which have a vital role in the human beings. The biological activity of the proteins is based on the structures of the proteins. One of the structural importance of the proteins is making the proteins a validate drug targets. In the present article DHFR enzyme...

  • MGBG in Combined Anticancer Chemotherapy. Gonçalves, R. F.; Kriechammer, G.; Marques, M. P. M. // Letters in Drug Design & Discovery;Dec2011, Vol. 8 Issue 10, p897 

    The combined activity of MGBG (metylglyoxal-bis(guanylhydrazone)) with either cisplatin or carboplatin was investigated, towards the human breast cancer cell line MCF-7. While a dose- and time-dependent cytotoxic activity was already observed for MGBG alone, a synergistic and non-reversible...

  • Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro. Qiao, Han; Wang, Ting-yu; Yan, Wei; Qin, An; Fan, Qi-ming; Han, Xiu-guo; Wang, Yu-gang; Tang, Ting-ting // Acta Pharmacologica Sinica;Sep2015, Vol. 36 Issue 9, p1085 

    Aim:Zoledronic acid (ZA), a bisphosphonate, is currently used in combination with chemotherapeutic agents to suppress breast cancer cell proliferation or breast cancer-induced osteolysis. The aim of this study was to investigate the effects of ZA combined with a natural anticancer compound...

  • TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast Cancer Maire, Virginie; Baldeyron, Céline; Richardson, Marion; Tesson, Bruno; Vincent-Salomon, Anne; Gravier, Eléonore; Marty-Prouvost, Bérengère; De Koning, Leanne; Rigaill, Guillem; Dumont, Aurélie; Gentien, David; Barillot, Emmanuel; Roman-Roman, Sergio; Depil, Stéphane; Cruzalegui, Francisco; Pierré, Alain; Tucker, Gordon C.; Dubois, Thierry // PLoS ONE;May2013, Vol. 8 Issue 5, p1 

    Triple-negative breast cancer (TNBC) represents a subgroup of breast cancers (BC) associated with the most aggressive clinical behavior. No targeted therapy is currently available for the treatment of patients with TNBC. In order to discover potential therapeutic targets, we searched for protein...

  • Letrozole: A Review of its Use in Postmenopausal Women with Breast Cancer. Simpson, Dene; Curran, Monique P.; Perry, Caroline M. // Drugs;2004, Vol. 64 Issue 11, p1213 

    Letrozole (Femara®), a nonsteroidal, third-generation aromatase inhibitor administered orally once daily, has shown efficacy in the treatment of postmenopausal women with early-stage or advanced, hormone-sensitive breast cancer. In early-stage disease, extending adjuvant endocrine therapy...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics